- |||||||||| riluzole / Generic mfg.
Review, Journal: Current Status of Drug Development for Amyotrophic Lateral Sclerosis (Pubmed Central) - Nov 16, 2024
Although riluzole and edaravone have been approved for the treatment of ALS, it remains a lethal disease that causes rapid motor impairment, and there is an urgent need to develop more effective treatments. Advances in understanding the pathomechanisms of ALS, efficient clinical trial design, and research support programs have led to many clinical trials for ALS both domestically and internationally.
- |||||||||| riluzole / Generic mfg.
Journal, Reflex: Synaptic dynamics linked to widespread elevation of H-reflex before peripheral denervation in amyotrophic lateral sclerosis. (Pubmed Central) - Nov 13, 2024
The ratio between maximal amplitudes of H-reflex and direct motor response increased in all muscles, irrespective of disease onset, and was found positively correlated with exaggerated osteotendinous reflexes and spasticity but depressed in patients on riluzole...It is speculated that spinal interneurons may compensate for potential depression of monosynaptic EPSPs in ALS. From a clinical perspective, while the added value of H-reflex to osteotendinous reflex evaluation may be limited, it can serve as a valuable quantitative biomarker of pyramidal dysfunction in clinical trials.
- |||||||||| PK/PD data, Preclinical, Journal: Development and validation of an LC-MS/MS method for simultaneous quantification of eight drugs in plasma and brain: Application in a pharmacokinetic study in mice. (Pubmed Central) - Nov 13, 2024
A selective and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous quantitation of a cassette of 8 drugs, including docetaxel, erlotinib, loperamide, riluzole, vemurafenib, verapamil, elacridar and tariquidar. Similarly, the precision for all compounds at three different concentration levels ranged below 15
- |||||||||| riluzole / Generic mfg.
Patients perspective on the financial burden of ALS in the Republic of Kazakhstan and a call for change (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_719;
The disease is one of the most expensive in terms of direct medical and non-medical costs, far exceeding the average per capita income in the RK. Societal assistance should be improved to reduce the burden on patients and caregivers and, consequently, the direct and indirect medical costs.
- |||||||||| riluzole / Generic mfg.
Interaction between riluzole treatment and dietary glycemic index in the disease progression of amyotrophic lateral sclerosis (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_684;
When quartile groups were used, GI second [b= 1.9, 95% CI 4.1 to 0.2, p = 0.07], third [b= 3.0, 95% CI 5.1 to 0.8, p < 0.01] and fourth [b= 2.2, 95% CI 4.3 to 0.01, p < 0.05] quartile groups were associated with less ALSFRS-r change between baseline and 3-months compared to the first quartile group among the RTG. Similarly, GL fourth quartile group was associated with less ALSFRS-r change to 3-month compared to the first quartile group [b= 2.6, 95% CI 4.7 to 0.5), p < 0.05] among the RTG.
- |||||||||| riluzole / Generic mfg.
Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_683;
From this cohort, 222 patients from the riluzole group were matched with 402 patients from the control group by PSM. In multivariate cox hazard regression, riluzole did not affect survival (p = 0.840) or change of ALSFRS (6 months: p = 0.089; 12 months: p = 0.255).
- |||||||||| riluzole / Generic mfg.
Palliative care in patients with ALS: population-based study from 2016 to 2024 (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_682;
We describe 63 ALS patients (58.7% males and 41.3% females) treated by the palliative care unit of Turin from 2016 to the present. Median age at first evaluation was 71.6 years and median duration of palliative treatment was 2.70 months, with home care being the most frequent setting (54% home only; 23.8% home
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, Radicava ORS (edaravone oral) / Mitsubishi Tanabe
Evolution of the treatment landscape for patients diagnosed with ALS in the United States (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_624;
Mitsubishi Tanabe Pharma America (MTPA) IV edaravone was introduced in 2017 and saw a consistent increase from 1 to 4.8% between 2017 and 2021. However, with the introduction of oral edaravone in 2022, the use of IV edaravone decreased to 1%, while the use of oral edaravone increased to 8.9%.
- |||||||||| Relyvrio (phenylbutyrate/taurursodiol) / Amylyx, Radicava (edaravone) / Mitsubishi Tanabe
Canadian regulatory framework and flexibility in the context of rare diseases with unmet medical need such as amyotrophic lateral sclerosis (ALS) (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_611;
Access to ALS Therapies in Canada: There are currently two available ALS treatments in Canada: RADICAVA (edaravone) and RILUTEK (riluzole)... HC follows rigorous scientific and regulatory processes for drug approval, while exercising flexibility within the regulatory framework to respond to the pressing need for rare diseases therapies, including ALS, for Canadian patients.
- |||||||||| A Systematic Literature Review on the Efficacy of Pharmacological Interventions in Ataxia () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1292;
Limited therapeutic options are available for ataxia, often focusing on symptomatic management rather than addressing the underlying cause. This SLR underscores a notable gap in treatments that directly target ataxia and highlights the potential pharmacological treatments in treating ataxia or slowing its progression.
- |||||||||| oxaliplatin / Generic mfg., riluzole / Generic mfg.
Trial completion date, Trial suspension, Trial primary completion date: RILUZOX-01: Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy. (clinicaltrials.gov) - Nov 4, 2024
P2, N=80, Suspended,
This SLR underscores a notable gap in treatments that directly target ataxia and highlights the potential pharmacological treatments in treating ataxia or slowing its progression. Trial completion date: Oct 2024 --> Mar 2025 | Active, not recruiting --> Suspended | Trial primary completion date: Sep 2024 --> Mar 2025
- |||||||||| riluzole / Generic mfg.
Retrospective data, Journal, HEOR: Health care resource utilization and costs across stages of amyotrophic lateral sclerosis in the United States. (Pubmed Central) - Oct 29, 2024
Using insurance claims data from the IBM MarketScan Databases between January 2013 and December 2019, we identified plwALS as having at least 2 claims at least 27 days apart with an ALS International Classification of Diseases, Ninth or Tenth Revision diagnosis code (335.20/G12.21) or at least 1 ALS diagnosis code and prescription filled for riluzole/edaravone...HCRU and costs increased with ALS progression, with diagnosis frequently occurring even after experiencing late-stage symptoms. These findings highlight the potential value of delaying progression into a more resource-intensive stage by diagnosing and adequately treating plwALS earlier in the disease course.
- |||||||||| Review, Journal: Exploring the Therapeutic Potential of N-Methyl-D-Aspartate Receptor Antagonists in Neuropathic Pain Management. (Pubmed Central) - Oct 26, 2024
This narrative review aims to provide a comprehensive examination of NMDAR antagonists, specifically ketamine, memantine, methadone, amantadine, carbamazepine, valproic acid, phenytoin, dextromethorphan, riluzole, and levorphanol, in the management of NeP. By analyzing and summarizing current preclinical and clinical studies, this review seeks to evaluate the efficacy of these pharmacologic agents in providing adequate relief for NeP.
- |||||||||| riluzole / Generic mfg.
Journal: A novel KCNC3 gene variant in the voltage-dependent Kv3.3 channel in an atypical form of SCA13 with dominant central vertigo. (Pubmed Central) - Oct 17, 2024
Treatment of our patient with riluzole, a drug that is known to also activate potassium channels, turned out to be partly beneficial...Thus, and most importantly, carefully elevated plasma potassium levels in the physiological range, or novel drugs attenuating Kv3.3 inactivation might provide novel therapeutic approaches to rescue potassium currents of SCA13 variants per se. In addition, our findings broaden the phenotypic spectrum of Kv3.3 variants, expanding it to atypical phenotypes of Kv3.3-associated neurological disorders.
- |||||||||| riluzole / Generic mfg.
Journal: BDNF augmentation reverses cranial radiation therapy-induced cognitive decline and neurodegenerative consequences. (Pubmed Central) - Oct 10, 2024
Moreover, riluzole (RZ)-mediated increased BDNF in vivo in the chemotherapy-exposed mice reversed cognitive decline...Dual-immunofluorescence staining, spatial transcriptomics, and biochemical assessment of RZ-treated irradiated brains demonstrated preservation of synaptic integrity and neuronal plasticity but not neurogenesis and reduced neuroinflammation concurrent with elevated BDNF levels and transcripts compared to vehicle-treated irradiated brains. In summary, oral administration of RZ represents a viable and translationally feasible neuroprotective approach against RICD.
- |||||||||| riluzole / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Riluzole Enhancing anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer. (Pubmed Central) - Oct 9, 2024
This combination showed greater efficacy than either single agent, and strongly suppressed tumor growth in vivo. Taken together, our studies indicate that riluzole activates cGAS/STING-mediated innate immune responses, which might be exploited to sensitize colorectal tumors to anti-PD-1/PD-L1 therapies.?.
- |||||||||| riluzole / Generic mfg.
Review, Journal: Association between motor neuron disease and HIV infection: A systematic review of case reports. (Pubmed Central) - Oct 3, 2024
This case report emphasizes the importance of considering ALS in the differential diagnosis of progressive motor dysfunction in younger patients and the complexities involved in their care. MND/ALS may present differently in the people living with HIV as a rapidly progressive disease in younger people but with the potential to improve weakness and survival through antiretroviral therapy.
- |||||||||| riluzole / Generic mfg.
Experimental Medicine to identify therapies in ALS (517d) - Oct 1, 2024 - Abstract #ALSMND2024ALS_MND_101;
Many trials involving tens of thousands of people over the last three decades have delivered a single globally licensed drug with only modest disease-modifying effect: riluzole...The route to a greater chance of success in trials designed to demonstrate clinical benefit (and de-risk the financial investment they require), lies in prioritising signals of pathway engagement or surrogate markers of therapeutic action in humans. The current potential for using neurofilament light chain group-level reduction as a drug prioritization platform, will be highlighted
- |||||||||| Review, Journal: Pharmacological management of secondary chronic spinal cord injury: a systematic review. (Pubmed Central) - Sep 28, 2024
Positive results in different areas have been observed in patients receiving the anti-spastic drugs tizanidine and baclofen or Granulocyte colony-stimulating factor. Growth hormone showed only minimal or no significant effects, and the therapy of secondary chronic SCI with riluzole has been poorly researched to date.
- |||||||||| Qalsody (tofersen) / Biogen
Review, Journal: Tofersen for SOD1 ALS. (Pubmed Central) - Sep 27, 2024
Tofersen, an antisense oligonucleotide that reduces expression of SOD1 via RNAase mediated degradation of SOD1 mRNA, has shown robust effects on ALS biomarkers. While a Phase III trial of tofersen failed to meet its primary end point, open label extension data suggests that tofersen slows progression of SOD1 ALS.
- |||||||||| riluzole / Generic mfg., sorafenib / Generic mfg.
Trial completion date, Metastases: Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (clinicaltrials.gov) - Sep 19, 2024
P1, N=35, Active, not recruiting,
While a Phase III trial of tofersen failed to meet its primary end point, open label extension data suggests that tofersen slows progression of SOD1 ALS. Trial completion date: Sep 2024 --> Sep 2025
- |||||||||| riluzole / Generic mfg., minocycline / Generic mfg.
Clinical, Journal: Pharmacologic Therapy for Spinal Cord Injury. (Pubmed Central) - Sep 12, 2024
Current clinical trials for pharmacotherapy and cellular transplantation following acute SCI are also reviewed. Despite the paucity of current evidence for clinically beneficial post-SCI pharmacotherapy, future research efforts will hopefully elucidate promising therapeutic agents to improve neurologic function.
- |||||||||| riluzole / Generic mfg.
Journal: The WFS1-ZnT3-Zn2+ Axis Regulates the Vicious Cycle of Obesity and Depression. (Pubmed Central) - Sep 11, 2024
Importantly, riluzole, a therapeutic molecule targeting the nervous system, in vivo administration prevents HFD-induced obesity and associated depression. Thus, a WFS1-ZnT3-Zn2+ axis critical is demonstrated for the vicious cycle of obesity and depression and that riluzole may have the potential to reverse this process against obesity and depression.
|
